title: Half-dose photodynamic therapy for chronic central serous chorioretinopathy: Efficacy and safety outcomes in real world.
abstract: OBJECTIVE
  To have an insight of the outcomes of half-dose photodynamic therapy (PDT) for patients with chronic central serous chorioretinopathy (CSC) in a real world population.
  
  
  METHODS
  This is a retrospective consecutive case series, one-centre study, with a 12-month follow-up period.
  
  
  RESULTS
  The study took into account 15 eyes of 13 patients. All patients were male in gender and only 1 eye belonged to a non-caucasian. The sample mean age was 51,27±11,66 (between 36 and 74 years); mean baseline best-corrected visual acuity (BCVA) was 0,40±0,25 logMAR and central macular thickness (CMT) was 411,40±88,44μm. All patients had subretinal fluid (SRF) and retinal pigment epithelium (RPE) detachment involving the fovea. In a month time, BCVA and CMT had remarkable improvements with only one eye not gaining letters. At 6-month visit, 46,7% of the eyes were provided with additional treatment (intra-vitreal anti-VEGF or PDT). In the final visit no eye had worsened more than 5 letters and 53,3% had a BCVA improvement of at least 5 letters, with only 2 eyes remaining with RPE detachment and SRF. There was a steady regression in CMT throughout the follow-up; 93,3% had CMT under 300μm and CMT mean was 249,93±72,78μm. There were no reported complications.
  
  
  CONCLUSIONS
  These results support PDT as a valuable approach for therapeutic decisions on chronic CSC as well as the need of other add up treatments for a better final outcome. Further evaluations with longer follow-up's should be taken into consideration for safety issues.
authors.affiliation: Resident of Ophthalmology. Centro Hospitalar Vila Nova de Gaia/Espinho Department of Ophthalmology, Vila Nova de Gaia, Portugal. Electronic address: filipe.neves@chvng.min-saude.pt.
authors.forename: Filipe
authors.initials: F
authors.lastname: Neves
authors.affiliation: Resident of Ophthalmology. Centro Hospitalar Vila Nova de Gaia/Espinho Department of Ophthalmology, Vila Nova de Gaia, Portugal.
authors.forename: João
authors.initials: J
authors.lastname: Costa
authors.affiliation: Consultant Ophthalmologist. Centro Hospitalar Vila Nova de Gaia/Espinho Department of Ophthalmology, Vila Nova de Gaia, Portugal.
authors.forename: Sofia
authors.initials: S
authors.lastname: Fonseca
authors.affiliation: Consultant Ophthalmologist. Centro Hospitalar Vila Nova de Gaia/Espinho Department of Ophthalmology, Vila Nova de Gaia, Portugal.
authors.forename: Luís
authors.initials: L
authors.lastname: Silva
authors.affiliation: Consultant Ophthalmologist. Centro Hospitalar Vila Nova de Gaia/Espinho Department of Ophthalmology, Vila Nova de Gaia, Portugal; Head of Department. Centro Hospitalar Vila Nova de Gaia/Espinho Department of Ophthalmology, Vila Nova de Gaia, Portugal.
authors.forename: Luís
authors.initials: L
authors.lastname: Agrelos
mesh_terms: D000328:Adult; D000368:Aged; D016022:Case-Control Studies; D056833:Central Serous Chorioretinopathy / Q000532:radiotherapy*; D004307:Dose-Response Relationship, Radiation; D006801:Humans; D008297:Male; D008875:Middle Aged; D017319:Photosensitizing Agents / Q000592:standards*; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D017319:Photosensitizing Agents
keywords: Central macular thickness; Chronic central serous chorioretinopathy; Half dose photodynamic therapy; Subretinal fluid; Verteporfin